NCT02306954 - Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

September 15, 2020

Study Completion Date

December 31, 2026

Conditions

Renal Cell Carcinoma

Interventions

BIOLOGICAL

High Dose IL-2

High Dose IL-2 is approved by the FDA for the treatment of renal cell cancer.

RADIATION

SBRT

Patients assigned to SBRT arm will receive two doses of SBRT at 20 Gy on the Wednesday and Friday before the Monday on which IL-2 starts.

Trial Locations (1)

Portland Providence Medical Center, Portland